トラネキサム酸

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P271：屋外または換気の良い場所でのみ使用すること。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

トラネキサム酸 価格

MSDS Information

• Amstat

トラネキサム酸 化学特性,用途語,生産方法

• 外観

  白色, 結晶～粉末

• 溶解性

  水に溶けやすく、エタノールに極めて溶けにくく、アセトンにほとんど溶けない。

• 解説

  トラネキサム酸，分解点392 ℃．水に可溶，エタノールに難溶．白血病，紫斑(はん)病，手術などの異常出血の止血に使用される．LD50  ＞ 1.2 g/kg(ラット，静注)．
  森北出版「化学辞典（第2版）

• 用途

  抗プラスミン剤です。プラ スミンがフィブリンに結合するのを阻害し、 フィブリン分解抑制作用を示します。

• 用途

  有機合成原料。

• 効能

  抗線溶薬, 抗炎症薬, プラスミン阻害薬

• 製造

  p-アセトアミノメチル安息香酸を触媒の存在下，高圧接触還元後，脱N-アセチル化すると得られるトラネキサム酸．

• 商品名

  トラネキサム酸 (日医工); トランサミン (ニプロファーマ); トランサミン (第一三共); トランサミン (第一三共)

• 説明

  Tranexamic acid is a derivative of aminomethylbenzoic acid, and a kind of antifibrinolytic drugs to stop bleeding. The hemostasis mechanism of tranexamic acid is similar to aminocaproic acid and aminomethylbenzoic acid, but the effect is stronger. The strength is 7 to 10 times of aminocaproic acid, 2 times of aminomethylbenzoic acid, but toxicity is similar.
  The chemical structure of tranexamic acid is similar to lysine, competitive inhibition of plasmin original in fibrin adsorption, to prevent their activation, protection fiber protein not to degrade by plasmin and dissolve, eventually achieve hemostasis. Applicable in the treatment of acute or chronic, localized or systemic primary fiber fibrinolytic hyperthyroidism caused by bleeding, such as obstetric hemorrhage, renal hemorrhage, hemorrhage of hypertrophy of the prostate, hemophilia, pulmonary tuberculosis hemoptysis, stomach bleeding, after operation of liver, lung, spleen and other viscera hemorrhage; also can be used in surgery when abnormal bleeding etc..
  Clinical tranexamic acid has effect significantly to insect bites disease, dermatitis and eczema, simple purpura, chronic urticaria, artificial sex urticaria, toxic eruption and eruption. And also has a certain effect on erythroderma, scleroderma, systemic lupus erythematosus (SLE), Erythema multiforme, shingles and alopecia areata. Treatment of hereditary angioedema effect is also good. In the treatment of Chloasma, general medicine is effective about 3 weeks, markedly effective 5 weeks, a course of 60 days. Given orally in doses of 0.25 ~ 0.5 g, a day 3 ~ 4 times. A few patients can nausea, fatigue, pruritus, abdominal discomfort, and diarrhea side effects after withdrawal symptoms disappear.

• 化学的特性

  Tranexamic acid is a White or almost white, crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether.

• 使用

  Fibrinolysis, the cleavage of fibrin by plasmin, is a normal step in the dissolution of fibrin clots after wound repair. Tranexamic acid is an inhibitor of fibrinolysis that blocks the interaction of plasmin with fibrin (IC50 = 3.1 μM). It is a lysine mimetic that binds the lysine binding site in plasmin. Antifibrinolytic agents have value when fibrinolytic activity is abnormally high or when coagulation is impaired.

• 定義

  ChEBI: Tranexamic acid is a monocarboxylic acid. It has a role as an antifibrinolytic drug and a hematologic agent. It is functionally related to a cyclohexanecarboxylic acid.

• 一般的な説明

  Tranexamic acid is an antifibrinolytic agent and is commonly used for heavy menstrual bleeding.

• 作用機序

  Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action.

• 副作用

  Tranexamic acid is mostly well-tolerated.
  Common
  nausea (upset stomach)
  vomiting (throwing up)
  diarrhea
  headache
  
  Occasional
  dizziness
  giddiness
  vision changes
  
  Rare
  stroke
  blood clots in undesired areas
  deep vein thrombosis

• 参考文献

  Intravenous use of tranexamic acid reduces postoperative blood loss in total knee arthroplasty DOI:10.1007/s00402-014-2081-x
  www.childrensmn.org
  dermnetnz.org
  Tranexamic acid for the prevention and treatment of postpartum haemorrhage. DOI:10.1097/01.aoa.0000552886.12061.3c
  Sittig's Pharmaceutical Manufacturing Encyclopedia
  The Renal Drug Handbook
  Synthesis of Essential Drugs (2006, Elsevier) - libgen.lc
  Spectrophotometric and spectrofluorimetric methods for the determination of tranexamic acid in pharmaceutical formulation. DOI:10.1248/CPB.55.364
  Determination of plasma tranexamic acid using cation-exchange high-performance liquid chromatography with fluorescence detection. DOI:10.1016/S0378-4347(00)84573-9
  [1] A Pilbrant, J Vessman, M Schannong. “Pharmacokinetics and bioavailability of tranexamic acid.” European Journal of Clinical Pharmacology 20 1 (1981): 65–72.    

トラネキサム酸 上流と下流の製品情報

トラネキサム酸 生産企業

Global(964)Suppliers

トラネキサム酸 スペクトルデータ(IR1、IR2、MS、Raman)

1197-18-8, トラネキサム酸 キーワード